Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

German meeting focuses on hyperthermia treatment therapy for cancer

BSD Medical : 02 May, 2007  (New Product)
BSD Medical hosted a summit meeting involving leading European medical and radiation oncologists to review the results and strategies for using hyperthermia treatment therapy to treat cancer patients.
The meeting took place at Atzelberg Castle near Erlangen, Germany.

The results of a 340 patient Phase III study involving high-risk soft tissue sarcoma patients were presented and reviewed, along with initiatives for important
research efforts in treating several other cancers.

The results of the Phase III sarcoma trial will be publicly released at the American Society of Clinical Oncology (ASCO) 2007 Annual Meeting to be held in Chicago, USA on June 1 to 5, 2007.

The ASCO Annual Meeting is considered the premier educational and scientific event in the oncology community, hosting attendees from all over the world.
ther important research on the use of hyperthermia therapy in treating cancer was a particular focus of the summit meeting.

Of greatest emphasis was the progress on research of better treatments for pancreatic cancer, colon/rectal cancer and bladder cancer.

In a Phase II Clinical trial at the University of Munich Medical School, 12 patients with advanced or metastatic pancreatic cancer who had already failed in the first line treatment with chemotherapy were given chemotherapy in conjunction with hyperthermia therapy.

The one year event free survival rate was 32 percent compared to an expected 18 percent survival rate at one year.

A plan for expanding this research has been advanced.

Another area of considerable interest is sparing bladder cancer patients the life-debilitating handicap of bladder removal as well as improving survival rates for bladder cancer.

In research involving 44 patients at Erlangen University Medical School, after removing the bladder tumour through the urethra, the remaining cancer cells were treated with combined chemotherapy and/or radiation plus hyperthermia therapy using the BSD-2000, with a complete remission rate of 96 to 100 percent for T1 and T2 tumours.

Research at Charite University Medical School of Humboldt University in Berlin and at other locations is being conducted on the treatment of rectal cancer with combined hyperthermia, radiation and chemotherapy.

The Berlin site is equipped with BSD Medical's most technologically sophisticated system, a BSD-2000 integrated with a Magnetic resonance imaging system (the BSD-2000/3D/MRI), allowing a state of the art approach to research on hyperthermia therapy.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo